Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2201 participants.

Also called NCT03560310

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,201 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03560310
Other papers using this trial's data
  • Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome The New England journal of medicine, 2025-12-11 DOI, PubMed 40888737

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Finland, Iceland, Norway, Sweden (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03560310. Randomized; no masking; primary purpose treatment. Start 2018-06-29 (actual); primary completion 2025-03-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
Acronym
TACSI
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor 90mg twice daily and ASA 75-100 mg daily
Intervention (Drug)
ASA 75-160 mg daily
Lead sponsor
Vastra Gotaland Region (class: other government)
Collaborator
Gothia Forum - Center for Clinical Trial (class: other)
Collaborator
Göteborg University (class: other)

Record details

Record id
cardio:ct-nct03560310
Content hash
4341c5b2e5dc0b62359593f0926cb1559ff51708265d43dfc5f49bc80e4e2f74